炎症标志物HLA-DR与中重度干眼病体征和症状的相关性
研究纳入三项中重度干眼病临床研究的311例患者基线数据,用流式细胞术检测印迹细胞学标本HLA-DR,并与临床体征和症状做相关性分析,同时比较1 mg/mL环孢素(CsA)与赋形剂治疗后的变化。HLA-DR与角膜荧光素染色相关性最强,与Schirmer试验、泪膜破裂时间及症状问卷相关性较弱;CsA治疗后HLA-DR荧光任意单位较赋形剂降低。
要点
- HLA-DR与角膜荧光素染色相关性最强(r=0.30,P<0.0001)。
- HLA-DR与Schirmer试验(r=-0.20)及泪膜破裂时间(r=-0.13)呈负相关。
- 两项研究中CsA治疗后HLA-DR荧光任意单位较赋形剂降低(P=0.022和P=0.021)。
核心结论
- 在干眼病临床研究中症状与体征常不一致,HLA-DR与角膜荧光素染色体征显著相关,与Schirmer试验相关性较低,与泪膜破裂时间及症状问卷相关性弱。
- HLA-DR被报道可用于监测干眼病抗炎疗效,CsA治疗期间HLA-DR降低证实了这一点。
- 结膜细胞HLA-DR表达有潜力作为生物标志物,在干眼病临床研究中桥接体征与症状,但仍需进一步验证研究。
研究设计与样本
- 基于三项中重度干眼病临床研究的基线数据,共分析311例患者。
- 用流式细胞术定量印迹细胞学标本中的HLA-DR,并分析治疗1 mg/mL环孢素(CsA)与赋形剂后的数据。
主要发现
- HLA-DR随Sjögren综合征诊断显著升高(P<0.0001),随睑板腺疾病诊断显著升高(P=0.0223)。
- HLA-DR与角膜荧光素染色相关性最强(r=0.30,P<0.0001)。
- HLA-DR与Schirmer试验呈显著负相关(r=-0.20,P=0.0003),与泪膜破裂时间呈显著负相关(r=-0.13,P=0.0226)。
- HLA-DR与眼表疾病指数总分(r=0.12,P=0.0426)及视觉模拟量表评分(r=0.14,P=0.0176)的相关性有统计学意义。
- 两项研究中CsA治疗后HLA-DR荧光任意单位较赋形剂有统计学降低(P=0.022和P=0.021)。
临床怎么用
- 作者认为结膜细胞HLA-DR表达有潜力作为生物标志物,在干眼病临床研究中桥接体征与症状。
- 作者指出仍需要额外的验证研究。
局限性
- 原文结论指出仍需要额外的验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate correlations of the inflammatory HLA-DR marker with clinical signs and symptoms commonly used to assess dry eye disease (DED) severity. METHODS: Baseline data were collected from three clinical studies conducted on moderate to severe DED patients. Characteristics of DED were analyzed and correlations were performed in 311 patients. Data were analyzed after treatment with 1 mg/mL cyclosporine (CsA) and vehicle. We quantified HLA-DR by flow cytometry in impression cytology specimens. RESULTS: We found HLA-DR significantly increased with diagnosis of Sjögren syndrome (P < 0.0001) and meibomian gland disease (P = 0.0223). The strongest significant correlation was seen with the corneal fluorescein staining (CFS, r = 0.30, P < 0.0001). Significant negative relationships were also found with Schirmer's test (r = -0.20, P = 0.0003) and tear break-up time (TBUT, r = -0.13, P = 0.0226). Correlations were statistically significant with total Ocular Surface Disease Index and visual analog scale scores (r = 0.12, P = 0.0426, and r = 0.14, P= 0.0176, respectively). We found HLA-DR arbitrary units of fluorescence were statistically reduced after CsA treatment compared to vehicle (P = 0.022 and P = 0.021 in two studies). CONCLUSIONS: In clinical research on DED, discrepancy is often observed between symptoms and signs. We found HLA-DR correlated significantly with CFS clinical signs and to a lower extent Schirmer's test and weakly with TBUT and symptom reporting questionnaires. HLA-DR was reported to be useful for monitoring anti-inflammatory efficacy treatments in DED, which was confirmed with the reduction of HLA-DR while on CsA treatment. Its expression by conjunctival cells has the potential to serve as a biomarker, bridging signs and symptoms in clinical research in DED, but there is still a need for additional validation studies.
引用
- Brignole-Baudouin F, Riancho L, Ismail D, et al. Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease. Invest Ophthalmol Vis Sci. 2017. PMID: 28448672. doi:10.1167/iovs.15-16555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。